Menu
02b-653x337_toraymixin_eaa

Sepsis and septic shock

TORAYMYXIN®

State-of-the-art therapy for patients with endotoxic septic shock

Septic shock is associated with an unacceptable high mortality and a significant economic burden to the sanitary system. Endotoxin is the most potent trigger of the septic cascade and during the progress of sepsis, endotoxin levels can increase up to 1000 fold, even when cultures result negative for Gram-negative bacteria.

Toraymyxin®  Polymyxin B hemoperfusion therapy – from Toray Medical Ltd. (Japan), is the state-of-the-art therapy for endotoxin removal in septic shock patients. More than 150,000 patients have been treated with this innovative therapy and more than 250 peer-reviewed articles have been published, demonstrating the beneficial effects on hemodynamics, organ function and mortality.

EAA™Endotoxin Activity Assay – is the only FDA approved diagnostic assay to detect endotoxin activity in human whole blood. The EAA™ diagnostic test is performed in less than 30 minutes. EAA™ is the diagnostic assay to identify patients with endotoxic septic shock.

chronic-kidney-disease-653x337

Chronic kidney disease

Filtryzer® PMMA

A personalized therapy based on the individual needs of each patient

acute-respiratory-failure-653x337

Acute respiratory failure

ProLUNG®

A minimally invasive extracorporeal CO2 removal system for ventilatory support

Focus on

ESICM-LIVES-2018-653x337px

ESICM LIVES 2018 – PARIS

Estor is present at the 31st ESICM LIVES 2018, 20 – 24 October, Paris, France.

SIAARTI-2018-653x337px

SIAARTI 2018 – PALERMO

Estor is present at the 72nd National Congress of the Italian Society of Anesthesia, Analgesia, Resuscitation and Intensive Care (SIAARTI), 10 – 13 October 2018, Palermo, Italy.

SIN-2018-653x337px

SIN 2018 – RIMINI

Estor is present at the 59th National Congress of the Italian Society of Nephrology (SIN), October 3-6, Rimini, Italy.